Are glucose readings sufficient to adjust insulin dosage?

Diabetes Technology and Therapeutics

Volumn 13, Issue 1, 2011, Pages 85-92

  Bashan, Eran ^a   Herman, William H ^b   Hodish, Israel ^a,b  

^a Hygieia Inc   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO;

ALGORITHM; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER PROGRAM; DOSE RESPONSE; DRUG DOSE TITRATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SOFTWARE;

EID: 78650592170     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0112     Document Type: Article

References (23)

1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB: Is glycemic control improving in U.S. adults? Diabetes Care 2008;31: 81-86.
2. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004;27: 17-20.
3. Schifferdecker E, Schmidt K, Boehm BO, Schatz H: Longterm compliance of intensified insulin therapy. Diabetes Res Clin Pract 1994;23:17-23.
4. Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HG, Grobbee DE: Refill compliance in type 2 diabetes mellitus: A predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf 2003;12:121-127.
5. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
6. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008;371:1073-1084.
7. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254-259.
8. Kennedy L, Herman WH, Strange P, Harris A: Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006;29:1-8.
9. Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA: DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-1013.
10. Davies M, Evans R, Storms F, Gomis R, Khunti K: Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: Sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 2007;9: 706-713.
11. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005;28: 1568-1573.
12. Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M: Adjust to target in type 2 diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008;31:1305-1310.
13. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
15. McMahon GT, Dluhy RG: Intention to treat-initiating insulin and the 4-T study. N Engl J Med 2007;357:1759-1761.
16. Riddle MC: Starting and advancing insulin for type 2 diabetes: Algorithms and individualized methods are both necessary. J Clin Endocrinol Metab 2008;93:372-374.
17. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-S61.
18. Heinemann L: Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682.
19. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004;27:1554-1558.
20. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ: A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002;25:2074-2080.
21. Tsui E, Barnie A, Ross S, Parkes R, Zinman B: Intensive insulin therapy with insulin lispro: A randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001;24:1722-1727.
22. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
23. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail- Beigi F, Banerji MA, Failor A, Hamilton B: Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33:721-727.